Publication | Closed Access

Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors

UrologySurvival OutcomesReal World PatientsGenitourinary CancerMedicinePharmacologyOptimal Psa ResponsePharmacotherapyProstatic DiseaseOncologyEndocrine-related Cancer